Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Multiple Sclerosis Therapeutic Market
Multiple Sclerosis Therapeutic Market Size
- Report ID: GMI11109
- Published Date: Aug 2024
- Report Format: PDF
Multiple Sclerosis Therapeutic Market Size
Multiple Sclerosis Therapeutic Market size was valued at around USD 25.5 billion in 2023 and is estimated to grow at 4.7% CAGR from 2024 to 2032. Multiple sclerosis therapeutics encompasses various treatments and medications used in the management of multiple sclerosis, a chronic autoimmune disease that affects the central nervous system (CNS). Multiple sclerosis leads to the degradation of the myelin sheath, the protective covering of nerve fibers, resulting in disrupted communication between the brain and the rest of the body.
The rising incidence of multiple sclerosis is a significant driver of market growth. For instance, according to the World Health Organization (WHO), multiple sclerosis affects over 2.8 million people worldwide, with a higher prevalence among young adults and females. This underscores the increasing demand for effective multiple sclerosis therapeutics, driving research and development efforts to introduce innovative treatments that address the growing patient population.
Additionally, advancements in drug development, a growing focus on personalized medicine, and a rising geriatric population are key factors driving market growth.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Multiple Sclerosis Therapeutic Market Size in 2023: | USD 25.5 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 4.7% |
| 2032 Value Projection: | USD 38.1 Billion |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 176 |
| Tables, Charts & Figures: | 287 |
| Segments covered: | Drug Class, Route of Administration, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Multiple Sclerosis Therapeutic Market Scope
